Mazdutide Phase 2 trial (NCT04904913)
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Chinese Overweight and Obese Subjects
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 328
- actual
- Start
- 8 Jun 2021 (actual)
- Primary completion
- 29 Mar 2023 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| IBI362 high dose | Experimental | Drug: IBI362 | high dose IBI362 administered subcutaneously (SC) once a week. |
| IBI362 low dose | Experimental | Drug: IBI362 | Low dose IBI362 administered subcutaneously (SC) once a week. |
| placebo | Placebo comparator | Other: placebo | placebo administered subcutaneously (SC) once a week. |
| IBI362 moderate dose | Experimental | Drug: IBI362 | moderate dose IBI362 administered subcutaneously (SC) once a week. |
| IBI362 extra high dose | Experimental | Drug: IBI362 | extra high dose IBI362 administered subcutaneously (SC) once a week. |
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent Change from Baseline in Body Weight | Baseline ,week 24 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Percentage of Participants who Achieve ≥5% Body Weight Reduction | Baseline, Week 24 |
| Percentage of Participants who Achieve ≥10% Body Weight Reduction | Baseline, Week 24 |
| Absolute change from Baseline in body weight | Baseline, Week 24 |
| Change from Baseline in Waist Circumference | Baseline, Week 24 |
| Change from Baseline in BMI | Baseline, Week 24 |
| Change from Baseline in HbA1c | Baseline, Week 24 |
| Change from Baseline in fasting plasma glucose | Baseline, Week 24 |
| Change from Baseline in systolic blood pressure | Baseline, Week 24 |
| Change from Baseline in diastolic blood pressure | Baseline, Week 24 |
| Change from Baseline in total cholesterol | Baseline, Week 24 |
| Change from Baseline in low-density lipoprotein cholesterol | Baseline, Week 24 |
| Change from Baseline in high-density lipoprotein cholesterol | Baseline, Week 24 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
The Chinese overweight and obesity phase 2 interim analysis
Adults with a BMI of 24 or more plus hyperphagia or a comorbidity, or a BMI of 28 or more, were randomised 3:1:3:1:3:1 to mazdutide or placebo, with percentage weight change at week 24 as the primary endpoint.[2]
A total of 248 participants were randomised: 62 to 3 mg, 63 to 4.5 mg, 61 to 6 mg and 62 to placebo.[2]
Week 24 weight results
Weight changed by -6.7%, -10.4% and -11.3% with mazdutide 3, 4.5 and 6 mg, against +1.0% with placebo.[2]
Diarrhoea, nausea and upper respiratory tract infection were the most common adverse events.[2]
Sources
- 1A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Chinese Overweight and Obese SubjectsClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.Nature communications · 2023PMID 38092790Accessed 2 Oct 2026
Found an error? Report a correction.